LPCN – Lipocine Inc

LPCN — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

2.21

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

0.11

EPS Last/This Y

-0.13

EPS This/Next Y

0.25

Price

2.25

Target Price

10.5

Analyst Recom

Performance Q

-76.21

Upside

-2,008.0%

Beta

0.48

Ticker: LPCN

22 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-04-23	LPCN	2.37	N/A	N/A	0
2026-04-24	LPCN	2.44	N/A	N/A	0
2026-04-27	LPCN	2.39	N/A	N/A	0
2026-04-28	LPCN	2.32	N/A	N/A	0
2026-04-29	LPCN	2.32	N/A	N/A	0
2026-04-30	LPCN	2.34	N/A	N/A	0
2026-05-01	LPCN	2.35	N/A	N/A	0
2026-05-04	LPCN	2.33	N/A	N/A	0
2026-05-05	LPCN	2.33	N/A	N/A	0
2026-05-06	LPCN	2.44	N/A	N/A	0
2026-05-07	LPCN	2.4	N/A	N/A	0
2026-05-08	LPCN	2.38	N/A	N/A	0
2026-05-11	LPCN	2.34	N/A	N/A	0
2026-05-12	LPCN	2.34	N/A	N/A	0
2026-05-13	LPCN	2.34	N/A	N/A	0
2026-05-14	LPCN	2.34	N/A	N/A	0
2026-05-15	LPCN	2.29	N/A	N/A	0
2026-05-18	LPCN	2.22	N/A	N/A	0
2026-05-19	LPCN	2.21	N/A	N/A	0
2026-05-20	LPCN	2.26	N/A	N/A	0
2026-05-21	LPCN	2.21	N/A	N/A	0
2026-05-22	LPCN	2.26	N/A	N/A	0
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

22 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-04-23	LPCN	2.36	-	-	-1.93
2026-04-24	LPCN	2.44	-	-	-1.93
2026-04-27	LPCN	2.38	-	-	-1.93
2026-04-28	LPCN	2.32	-	-	-1.93
2026-04-30	LPCN	2.35	-	-	-1.93
2026-05-01	LPCN	2.34	-	-	-1.93
2026-05-04	LPCN	2.29	-	-	-1.93
2026-05-05	LPCN	2.34	-	-	-1.93
2026-05-06	LPCN	2.44	-	-	-1.93
2026-05-07	LPCN	2.40	-	-	-1.93
2026-05-08	LPCN	2.40	-	-	-1.93
2026-05-11	LPCN	2.33	-	-	-1.93
2026-05-12	LPCN	2.34	-	-	-1.93
2026-05-13	LPCN	2.32	-	-	-1.93
2026-05-14	LPCN	2.34	-	-	-1.93
2026-05-15	LPCN	2.27	-	-	-1.93
2026-05-18	LPCN	2.21	-	-	-1.93
2026-05-19	LPCN	2.21	-	-	-1.93
2026-05-20	LPCN	2.25	-	-	-1.90
2026-05-21	LPCN	2.21	-	-	-1.90
2026-05-22	LPCN	2.25	-	-	-1.90
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

22 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-04-23	LPCN	102.77	13.02	2.03
2026-04-24	LPCN	102.72	13.02	2.03
2026-04-27	LPCN	102.72	11.71	2.22
2026-04-28	LPCN	133.64	11.71	2.22
2026-04-29	LPCN	133.73	11.71	2.22
2026-04-30	LPCN	108.49	11.71	2.22
2026-05-01	LPCN	108.49	11.71	0
2026-05-04	LPCN	108.50	11.71	2.02
2026-05-05	LPCN	108.50	11.71	2.02
2026-05-06	LPCN	108.49	11.71	2.02
2026-05-07	LPCN	108.50	11.71	2.02
2026-05-08	LPCN	108.53	11.71	2.02
2026-05-11	LPCN	102.66	14.84	1.97
2026-05-12	LPCN	102.66	14.84	2.22
2026-05-13	LPCN	102.64	14.84	2.22
2026-05-14	LPCN	102.66	14.84	2.22
2026-05-15	LPCN	102.64	14.84	2.22
2026-05-18	LPCN	102.69	12.47	2.21
2026-05-19	LPCN	125.67	12.47	2.21
2026-05-20	LPCN	125.64	12.47	2.21
2026-05-21	LPCN	125.60	12.47	2.21
2026-05-22	LPCN	125.59	12.47	2.21
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

22 items 1 of 1

Last Quarter Act. EPS

-0.54

Avg. EPS Est. Current Quarter

-0.4

Avg. EPS Est. Next Quarter

-0.43

Insider Transactions

125.59

Institutional Transactions

12.47

Beta

0.48

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

-93.8

Target Price

10.5

P/E

Forward P/E

PEG

P/S

9.31

P/B

0.74

P/Free Cash Flow

EPS

-1.96

Average EPS Est. Cur. Y

-1.9

EPS Next Y. (Est.)

-1.65

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-571.1

Relative Volume

0.15

Return on Equity vs Sector %

-77.1

Return on Equity vs Industry %

-61.5

EPS 1 7Days Diff

EPS 1 30Days Diff

0.11

EBIT Estimation

◆ LPCN Healthcare

$2.26

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

0/20

Pullback

16/25

Volume

11/15

Valuation

12/20

TP/AR

3/10

Options

0/10

RSI

33.8

Range 1M

36.8%

Sup Dist

4.4%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

0/25

Growth

9/30

Estimates

5/20

Inst/Vol

5/15

Options

0/10

EPS Yr

-12.7%

EPS NY

13.4%

52W%

4.3%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +364.6% upside

Quality

6/30

Valuation

16/30

Growth

7/25

Stability

7/10

LT Trend

1/5

Upside

+364.6%

Quality

Lipocine Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 14

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. It also develops LPCN 1154 (BRLIZIO), an oral neuro-steroid in a Phase 3 pivotal trial for postpartum depression; LPCN 1148, a prodrug of testosterone and testosterone laurate that has completed a Phase 2 trial for the management of decompensated cirrhosis; LPCN 1107, an oral hydroxy progesterone caproate product that has completed a Phase 2 trial for the prevention of recurrent preterm birth; LPCN 1144, an oral prodrug of bioidentical testosterone that has completed a Phase 2 trial for pre-cirrhotic non-alcoholic steatohepatitis; and LPCN 2401, an oral formulation comprising a proprietary anabolic androgen receptor agonist that is in a Phase 2 trial to manage incretin mimetic use in obesity management. In addition, the company is developing LPCN 2201, an oral brexanolone formulation that has completed a Phase 1 trial for major depressive disorders; LPCN 2203, an oral candidate that has completed a Phase 1 trial for management of essential tremor; and LPCN 2101, a neuroactive steroids (NAS) candidate that has completed a Phase 1 trial for drug-resistant epilepsy and women with epilepsy. The company's products focus on neurological and psychiatric central nervous system (CNS) disorders, liver disease, and hormone supplementation in the United States. It has a collaboration with Verity Pharmaceuticals, Inc. to develop and commercialize TLANDO; and TLANDO XR (LPCN 1111), a once-daily oral product candidate that has completed a Phase 2 trial for testosterone replacement therapy. Lipocine Inc. was founded in 1997 and is headquartered in Salt Lake City, Utah.

LPCN

Latest News

—

Caricamento notizie per LPCN…

stock quote shares LPCN – Lipocine Inc Stock Price stock today

news today LPCN – Lipocine Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch LPCN – Lipocine Inc yahoo finance google finance

stock history LPCN – Lipocine Inc invest stock market

stock prices LPCN premarket after hours

ticker LPCN fair value insiders trading

LPCN – Lipocine Inc

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: LPCN

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y